

C L A I M S

1. Rosiglitazone maleate crystalline form II having a powder diffraction spectrum to X-rays with the following principal absorptions:

Angle (2 θ)	d (Å)	Rel. Intens. (I/I ₀)
7.615	11.5998	7.4
8.985	9.8340	4.8
9.740	9.0733	9.3
13.635	6.4889	11.6
14.015	6.3138	7.1
15.320	5.7788	100.0
17.105	5.1796	43.8
17.910	4.9485	21.8
19.255	4.6058	16.7
20.330	4.3646	27.8
20.765	4.2741	21.7
22.285	3.9859	37.8
23.730	3.7464	14.1
24.610	3.6144	37.7
25.485	3.4922	27.0
27.030	3.2960	24.4
27.440	3.2477	17.0
28.135	3.1690	8.7
29.225	3.0533	12.7
29.905	2.9854	24.1
31.645	2.8251	11.5

2. Rosiglitazone maleate crystalline form II having a powder diffraction spectrum to X-rays as shown in Figure 4.

3. Rosiglitazone maleate crystalline form II having a DSC graph as shown in Figure 2.
4. Rosiglitazone maleate crystalline form II having an IR spectrum as shown in Figure 6.
5. Pharmaceutical compositions containing rosiglitazone maleate crystalline form II according to claims 1-4 together with pharmaceutically acceptable excipients and/or adjuvants.
6. Use of rosiglitazone maleate crystalline form II according to claims 1-4 for the preparation of pharmaceutical compositions for the treatment of diabetes.
7. A process for the crystallization of rosiglitazone maleate form I characterized in that it comprises the following steps:
 - a. heating to reflux an approximately equimolar mixture of rosiglitazone base and maleic acid in a solvent selected from alcohols, esters and/or ethers;
 - b. cooling said mixture to ambient temperature;
 - c. filtration and washing of the product;
 - d. desiccation.
8. A process according to claim 7, characterized in that said alcohols and/or esters are selected from isopropanol, ethyl acetate and/or isopropyl acetate.
9. A process according to claim 7, characterized in that said mixture is maintained under reflux for a time ranging between about 20 and 40 minutes

10. A process for the crystallization of rosiglitazone maleate form II, characterized in that it comprises the following steps:

a. heating to reflux an approximately equimolar mixture of rosiglitazone base and maleic acid in water;

b. cooling said mixture to ambient temperature;

c. filtration and washing of the product;

d. desiccation.

11. A process according to claims 10, characterized in that said mixture is maintained under reflux for a time ranging between about 20 and 40 minutes.